Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.070 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2026 Add to My Watchlist

Price and Volume

Volume	0
Open	9.070
Bid (Size)	8.920 (200)
Ask (Size)	10.48 (100)
Prev. Close	9.070
Today's Range	9.070 - 9.070
52wk Range	4.320 - 11.80
Shares Outstanding	45,047,449
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Prothena (NASDAQ:PRTA) Smashes Q1 Estimates on $50 Million Milestone Payment, Shares Steady ↗

May 07, 2026

Via Chartmill

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

May 07, 2026

From Prothena Corporation plc

Via Business Wire

Performance

YTD	-1.4%	-1.4%
1 Month	-15.9%	-15.9%
3 Month	+1.2%	+1.2%
6 Month	-12.5%	-12.5%
1 Year	+22.6%	+22.6%

More News

Prothena to Report First Quarter 2026 Financial Results on May 7

April 30, 2026

From Prothena Corporation plc

Via Business Wire

What's going on in today's after hours session ↗

April 27, 2026

Via Chartmill

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

April 27, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Corporation (NASDAQ:PRTA) Reports Q4 2025 Revenue Miss, Highlights Pipeline Progress and 2026 Cash Guidance ↗

February 19, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Prothena Announces Leadership Team Updates

April 10, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

March 21, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

March 09, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Announces up to $100 Million Share Repurchase Plan

February 27, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

February 19, 2026

From Prothena Corporation plc

Via Business Wire

Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

February 12, 2026

From Prothena Corporation plc

Via Business Wire

Prothena Announces Board of Directors Update

December 12, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

November 19, 2025

From Prothena Corporation plc

Via Business Wire

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗

November 12, 2025

Via Benzinga

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

November 11, 2025

From Prothena Corporation plc

Via Business Wire

Prothena Corp PLC (NASDAQ:PRTA) Reports Q3 2025 Earnings and Key Pipeline Milestones ↗

November 06, 2025

Via Chartmill

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

November 06, 2025

From Prothena Corporation plc

Via Business Wire

Prothena to Report Third Quarter 2025 Financial Results on November 6

October 30, 2025

From Prothena Corporation plc

Via Business Wire

Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings) ↗

October 07, 2025

Via Benzinga

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

October 01, 2025

From Prothena Corporation plc

Via Business Wire

Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 02, 2025

Via Benzinga

FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy ↗

August 29, 2025

Via Benzinga

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

August 28, 2025

From Prothena Corporation plc

Via Business Wire

Frequently Asked Questions

Is Prothena Corporation plc - Ordinary Shares publicly traded?

Yes, Prothena Corporation plc - Ordinary Shares is publicly traded.

What exchange does Prothena Corporation plc - Ordinary Shares trade on?

Prothena Corporation plc - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Prothena Corporation plc - Ordinary Shares?

The ticker symbol for Prothena Corporation plc - Ordinary Shares is PRTA on the Nasdaq Stock Market

What is the current price of Prothena Corporation plc - Ordinary Shares?

The current price of Prothena Corporation plc - Ordinary Shares is 9.070

When was Prothena Corporation plc - Ordinary Shares last traded?

The last trade of Prothena Corporation plc - Ordinary Shares was at 05/19/26 04:00 PM ET

What is the market capitalization of Prothena Corporation plc - Ordinary Shares?

The market capitalization of Prothena Corporation plc - Ordinary Shares is 408.58M

How many shares of Prothena Corporation plc - Ordinary Shares are outstanding?

Prothena Corporation plc - Ordinary Shares has 409M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.